Immuno-oncology

GCR are a leader in immuno-oncology innovation.

Immuno-oncology, one of the pillars of cancer treatment, is driving engagement worldwide among biotech, large pharma, universities/cancer centres and the financial investment community.

Currently, more than 130 biotech and 20 pharma companies are developing immuno-oncology therapies, according to the March 2016 Tufts Center for the Study of Drug Development (CSDD) report. That activity, Tufts CSDD said, reflects — and is fueling — worldwide immuno-oncology product sales, with annual revenues expected to reach $25 billion to $40 billion by 2020, up from $2.5 billion in 2015.

Immuno-oncology